Boston, MA 05/13/2014 (wallstreetpr) – Recently, Inovio Pharmaceuticals Inc (NYSEMKT:INO) has divulged the first quarter financial results for 2014. The results do not look favorable. The net loss for the company has increased as compared to the Q1 of 2013. But there has also been in an increase, in the revenue.
However, Inovio Pharmaceuticals needs to not only report better revenue but also increasing profits on a yearly as well as quarterly basis, in order to achieve progress. The company needs to put in many efforts and implement a set of strategies as cutting down costs or restructuring so as to make it work and begin its journey towards growth and development.
Q1 financial results published
Inovio Pharmaceuticals Inc (NYSEMKT:INO) has in a press release dated May 12; 2014 has published the first quarter earnings for the year 2014. The company has reported a total revenue to amount to the sum of $2.4 million, which has increased from $1.5 million as reported in the Q1 of 2013.
Inovio Pharmaceuticals has published the operating expenses of the company to be $12.4 million, which has also increased from $8.1 million reported in the Q1 of 2013. The company has divulged the losses from operations excluding other expenses have amounted to the sum of $10 million, which is equivalent to a loss per share of $0.05 million. This loss has also increased as compared to the $6.6 million, which is equivalent to $0.04 loss per share, as reported in the Q1 of 2013.
Inovio Pharmaceuticals has posted a net loss that is attributable to the common stockholders of the company as $10.8 million, which is equivalent to a loss per share of $0.05. This loss has also witnessed an increase on a year-over-year basis. By the end of tis quarter the cash equivalents of Inovio Pharmaceuticals Inc (NYSEMKT:INO) amounted to the sum of $116.8 million, which has increased from the amount equivalent to $52.6 million reported last year.
